NASDAQ$DSGN
Design Therapeutics Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Highlighted clinical and research progress and reported first quarter 2022 financial results.
Design Therapeutics reported its Q1 2022 financial results, highlighting the initiation of a Phase 1 trial for DT-216 in Friedreich Ataxia and promising preclinical data for Fuchs Endothelial Corneal Dystrophy. The company's cash position stands strong at $371.2 million.
- Initiated Phase 1 trial for DT-216, a GeneTAC molecule, for Friedreich Ataxia treatment.
- Presented promising new data for a GeneTAC candidate for Fuchs Endothelial Corneal Dystrophy (FECD).
- DT-216 was granted Fast Track designation by the FDA for Friedreich Ataxia treatment.
- Completed dosing in the first single-ascending dose cohort of Phase 1 study.
Headline financials
Revenue & EPS history
Design Therapeutics · Revenue · Quarterly
$0
Forward guidance
Design Therapeutics is focused on advancing its clinical and research programs, with topline Phase 1 data for DT-216 expected in the second half of 2022 and continued preclinical development of its FECD GeneTAC program.
Tailwinds
- Topline Phase 1 data on-track for second half of 2022.
- DT-216 has potential as a disease-modifying treatment for Friedreich ataxia.
- DT-216 was well tolerated at dose levels projected to achieve concentrations in the CNS, heart and skeletal muscle.
- FECD GeneTAC molecules led to robust reductions in toxic nuclear RNA foci of up to 99% in a time- and concentration-dependent manner.
- Strong cash position to support multi-year operating runway.
Headwinds
- Clinical trial and patient enrollment may face difficulties or delays.
- Promising early research or clinical trials may not demonstrate safety and/or efficacy in later preclinical studies or clinical trials.
- Changes in Design’s plans to develop its product candidates.
- Uncertainties associated with performing clinical trials, regulatory filings and applications.
- Reliance on third parties to successfully conduct clinical trials and preclinical studies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2022
-2.2%
Avg return
Earnings day
+1.7%
Avg return
5 days after
+3.2%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+15.1%
Q4 2023
Best reaction
-71.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.0% | +3.8% | -16.2% | |
| Q4 2025 | +3.2% | +0.7% | +26.1% | |
| Q3 2025 | +10.7% | +10.8% | +42.2% | |
| Q2 2025 | -8.9% | +14.5% | +48.3% | |
| Q1 2025 | +0.3% | +10.3% | +10.3% | |
| Q4 2024 | +0.4% | +2.5% | -27.2% | |
| Q3 2024 | -1.9% | +16.3% | +7.9% | |
| Q1 2024 | +1.7% | -3.0% | -17.9% | |
| Q4 2023 | +15.1% | +50.8% | +48.4% | |
| Q3 2023 | +13.9% | +10.4% | +27.4% | |
| Q2 2023 | -71.7% | -72.8% | -65.2% | |
| Q1 2023 | -12.2% | -12.6% | -26.4% | |
| Q4 2022 | -0.6% | -8.1% | -24.8% | |
| Q3 2022 | -0.3% | -0.8% | -9.7% | |
| Q2 2022 | +0.3% | +13.5% | +5.5% | |
| Q1 2022 | -1.5% | -2.4% | +30.9% | |
| Q4 2021 | -1.8% | -0.8% | -10.0% | |
| Q3 2021 | +4.8% | +10.7% | -3.8% | |
| Q2 2021 | +9.9% | +7.9% | +19.7% | |
| Q1 2021 | -6.0% | -18.0% | -1.8% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro